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Objective: To illustrate the utility of statistical monitoring boundaries in meta-analysis, and 
provide a framework in which meta-analysis can be interpreted according to the adequacy of 
sample size. To propose a simple method for determining how many patients need to be random-
ized in a future trial before a meta-analysis can be deemed conclusive.
Study design and setting: Prospective meta-analysis of randomized clinical trials (RCTs) 
that evaluated the effectiveness of isoniazid chemoprophylaxis versus placebo for preventing 
the incidence of tuberculosis disease among human immunodeficiency virus (HIV)-positive 
individuals testing purified protein derivative negative. Assessment of meta-analysis precision 
using trial sequential analysis (TSA) with LanDeMets monitoring boundaries. Sample size 
determination for a future trials to make the meta-analysis conclusive according to the thresholds 
set by the monitoring boundaries.
Results: The meta-analysis included nine trials comprising 2,911 trial participants and yielded 
a relative risk of 0.74 (95% CI, 0.53–1.04, P = 0.082, I2 = 0%). To deem the meta-analysis 
conclusive according to the thresholds set by the monitoring boundaries, a future RCT would 
need to randomize 3,800 participants.
Conclusion: Statistical monitoring boundaries provide a framework for interpreting 
meta-analysis according to the adequacy of sample size and project the required sample size 
for a future RCT to make a meta-analysis conclusive.
Keywords: meta-analysis, trial sequential analysis (TSA), randomized clinical trials (RCTs), 
isoniazid chemoprophylaxis, adequacy of sample size, human immunodeficiency virus (HIV), 
tuberculosis, purified protein derivative negative
Introduction
Meta-analyses of randomized clinical trials (RCTs) are considered the highest level 
of evidence for assessment of the benefits and harms of an intervention.1,2 While 
comprehensively conducted meta-analyses may provide strong inferences about the 
quality and generalizability of the available evidence,1–3 they can provide misleading 
or inadequate inferences about the reliability of the evidence, the consistency of 
evidence, and the definitive effectiveness of a treatment.4–11 This is particularly the Clinical Epidemiology 2010:2 58
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case when an insufficient number of events and patients exist 
from trials that have been pooled.6–10,12,13
As with conventional RCTs, we require an estimate 
of the reliability of the evidence according to statistical 
inferences made possible through an adequate number of 
events and patients in the individual trials.14 Many now 
claim that it is unethical to conduct a clinical trial with 
an insufficient sample size, as inferences of effectiveness 
may be insufficient to make clinical recommendations.15 
While we do not believe this is an issue of ethics,16 a similar 
clinical difficulty arises in interpreting meta-analysis if the 
analysis includes an insufficient number of trials, patients, 
and ultimately, events.6–8,10–13 While sample size calculations 
are almost consistently mandated for single trials,17 there has 
been comparatively little discussion of the need for adequate 
power in a meta-analysis.
Systematic evaluations reveal that many published 
meta-analysis and systematic reviews are deemed inconclusive 
or moderately conclusive by authors.18 Meta-analyses are 
frequently updated and subjected to significance testing as 
new trials emerge. This scenario is akin to interim analyses 
and data monitoring in RCTs, where data safety monitoring 
committees (DSMBs) meet at planned and/or unplanned times 
to discuss if the interim results are sufficiently convincing 
to recommend termination of the trial and conclude that the 
experimental treatment is superior, equivalent, or inferior to 
the control treatment.6–8,10,12,13,19,20 In this setting, DSMBs rely 
on sample size calculations and use of formal monitoring 
boundaries to control the risk of false positive and overly 
positive findings caused by the play of chance (random error) 
and/or repeated significance testing (multiplicity).20–22
Some argue that the reliability of the evidence in a 
meta-analysis should only be established in rigorous 
decision-making frameworks similar to those of DSMBs for 
single RCTs.6,7,19 The sample size required for a conclusive 
and reliable meta-analysis has typically been referred to 
as the required or optimal information size,6–8,10,11 The 
concatenation of meta-analysis, information size calculations 
and formal monitoring boundaries (or stopping rules), such 
as the Lan-DeMets alpha-spending monitoring boundary, 
has been dubbed trial sequential analysis (TSA) – analogous 
to group sequential analysis in single RCTs.10 A growing 
body of evidence from empirical studies, simulation studies, 
and application examples has underlined the importance 
of incorporating TSA to achieve reliable answers in 
meta-analysis and systematic reviews.6–9,12,13,23–28 In addition, 
TSA may be useful for determining how many patients need 
to undergo further randomization before the meta-analysis 
can be deemed conclusive and reliable.8,10,12,13,19 Thus, 
determining the sample size of future RCTs in the setting of 
a prospective meta-analysis using TSA may be preferable 
to conventional sample size calculations.16,29
To illustrate the utility of TSA in meta-analysis, we apply 
it to a pressing clinical and public health issue, the use of 
isoniazid chemoprophylaxis (IHZ) for tuberculosis (TB) 
disease in purified protein derivative negative (PPD) human 
immunodeficiency virus (HIV)-infected individuals.
Isoniazid chemoprophylaxis (IHZ)
IHZ has long been considered an effective chemoprophylaxis 
for preventing TB incidence among HIV-infected individuals, 
particularly among those testing positive for purified pro-
tein derivative (PPD+).30,31 However, the impact of IHZ has 
remained unclear among those who are testing PPD-, many 
of whom may have cutaneous anergy related to advanced 
HIV progression. Existing analyses have been limited by 
weak inferences about the effectiveness of IHZ in this 
population.32 Trials evaluating the effectiveness of IHZ 
among PPD- HIV-infected individuals have thus continued 
to use placebo controls.33–35 Given the unacceptably high 
mortality rates among HIV-positive and TB co-infected 
individuals,36 there is a critical need to establish definitively 
whether IHZ can effectively prevent TB among individuals 
who test PPD-. We aimed to evaluate the effectiveness of 
IHZ for prevention of TB disease among HIV-positive adults 
testing PPD.37–40
Methods
Eligibility criteria
We included any RCT that evaluated the effectiveness of 
IHZ chemoprophylaxis versus placebo for preventing the 
incidence of TB among HIV-positive individuals testing 
PPD-. We included studies from any location and of any 
duration. Due to difficulties associated with diagnosis of TB 
among HIV-positive infants and children,41 we focused our 
review of studies on adult populations and excluded those 
evaluating the effect of IHZ versus placebo on younger age 
groups (13 years). We excluded studies where participants 
had current or previous diagnosis of TB. We included studies 
where patients had negative PPD skin tests. We defined our 
primary outcome as active TB, probable or confirmed by 
microbiological, histological, or clinical methods.
Search strategy
In consultation with a medical librarian, we established 
a search strategy (available from corresponding author Clinical Epidemiology 2010:2 59
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on request). We searched independently, in duplicate, the 
following 10 databases (from inception to August 2009): 
MEDLINE; EMBASE (Exerpta Medica); Cochrane Central 
Register of Controlled Trials (CENTRAL); Allied and 
Complementary Medicine Database (AMED); Cumulative 
Index to Nursing and Allied Health Literature (CINAHL); 
TOXNET; Development and Reproductive Toxicology; 
Hazardous Substances Databank; Psych-info; and Web 
of Science, that included the full text of journals (OVID, 
ScienceDirect, and Ingenta, including articles in full text 
from approximately 1700 journals since 1993). In addition, 
we searched the bibliographies of published systematic 
reviews.30–32 We contacted the authors of studies for 
clarifications, where required.
Study selection
Two investigators (AA, EM) working independently, in dupli-
cate, scanned all abstracts and obtained the full-text reports 
of records, that indicated or suggested that the study met 
inclusion criteria for the outcomes of interest. After obtain-
ing full reports of the candidate trials the same reviewers 
independently assessed eligibility from full text papers. We 
judged RCTs to be of adequate quality if their generation 
of allocation sequences was unpredictable, if methods of 
allocation concealment ensured patients and investigators 
could not foresee treatment assignment, and if patient attrition 
was clearly described.
Data collection
The same two reviewers conducted data extraction indepen-
dently using a standardized pre-piloted form. Reviewers col-
lected information about the: study date; location; duration; 
trial size; mean age of participants; treatment regimens of 
control and active arms; and incidence of TB. We entered the 
data into an electronic database such that duplicate entries 
existed for each study, when the two entries did not match, 
we resolved differences by consensus.
Data analysis
We first calculated the Phi(Φ)-statistic in order to assess 
inter-rater reliability on inclusion of articles. This provides 
a measure of inter-observer agreement independent of 
chance.42 We calculated the pooled relative risk (RR) using 
the DerSimonian-Laird random-effects meta-analysis.3,43 
We calculated the I2 statistic for each analysis as a measure 
of the proportion of the overall variation that is attributable 
to between-study heterogeneity.44 Forest plots displaying 
individual study RR with 95% confidence intervals (CIs), 
and the DerSimonian-Laird pooled estimate were conducted 
using Review Manager version 5.2
TSA and meta-analysis sample  
size requirements
A single-trial sample size calculation is typically based on 
expected event rates, expected relative risks, an alpha set 
at 0.05, and power of 0.80.45 In meta-analysis, however, 
more conservative alpha and beta-levels may be required 
to ensure that the evidence is sufficiently compelling to 
justify recommendation of the experimental treatment 
for widespread use, or to ensure that the evidence is so 
convincing that further RCTs are not required.6,7,19 Due to 
heterogeneity across included trial populations, treatments 
and methods, the required meta-analysis information size 
additionally need adjustment for variation across trials.8,10–13 
Such adjustments are analogous to adjustments for variation 
across centers in a multi-center trial as they account for the 
proportion of total meta-analysis variation expected to be 
explained by variation across (and not within) trials.8,10,11
We determined the required meta-analysis information 
size for detecting a 25% relative risk reduction in TB, 
assuming a control group incidence rate of 5% (approximately 
the median rate across trials) and assuming that 20% of the 
total variation in the meta-analysis would be explained by 
variation across trials (heterogeneity). We calculated the 
information size required to yield “moderate” meta-analytic 
evidence based on an alpha = 5% significance level, 
and beta = 20% (80% power). We also calculated the 
information size required to yield “strong” meta-analytic 
evidence based on an alpha = 1% significance level, and 
beta = 10% (90% power).
Significance testing in RCTs and meta-analysis make 
use of a standardized test statistic (Z-statistic) which can be 
transformed to a P-value and subsequently used to evalu-
ate if the observed effects in the two treatments groups differ 
significantly. Z-statistics that lie outside the interval -1.96 to 
1.96 correspond to P-values smaller than 0.05, and Z-statis-
tics that lie outside the interval -2.57 to 2.57 correspond to 
P-values smaller than 0.01. In monitoring of RCTs it is com-
mon to establish formal stopping rules for the Z-statistic rather 
than the P-value.46 In this vein, group sequential monitoring 
boundaries for the cumulative Z-statistic are calculated every 
time a new group of randomized patients are added to the 
analysis up till the point where the number of patients random-
ized surpasses the required sample size.21,22,46 In meta-analysis, 
the monitoring boundaries may be applied analogously every 
time one or more trials are added up till the point where the Clinical Epidemiology 2010:2 60
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number of patients in the meta-analysis surpasses the required 
meta-analysis information size.6–8,10,12,13
We applied TSA by utilizing the Lan-DeMets alpha-
spending approach with monitoring boundaries corre-
sponding to the O’Brien-Fleming boundaries to assess the 
reliability of pooled inferences from our meta-analysis on 
TB.10,22 Three systematic reviews on the topic have previ-
ously been published in year 1998, 1999, and 2004.30–32 We 
therefore constructed monitoring boundaries to test for sta-
tistical significance in the meta-analysis including all trials 
up to year 1998, up to year 1999, and up to year 2004, albeit 
no new trials were published in 1999.
Topping up a sample size evaluation
Consider the situation where a new RCT on a topic is in the 
planning stage and where a fully updated meta-analysis on the 
same topic is deemed inconclusive. Once the RCT is completed 
(published) it will be added to the meta-analysis. The question 
then remains, how large does the new RCT need to be to make 
the meta-analysis conclusive? In our example, we deemed 
the meta-analysis conclusive once the cumulative Z-statistic 
crossed the statistical monitoring boundaries constructed 
with TSA. Because we performed meta-analysis information 
size calculations to achieve both moderate (alpha = 5% and 
beta = 20%) and strong (alpha = 1% and beta = 10%) evidence 
and constructed the statistical monitoring boundaries separately 
for each degree of evidence, we made similar distinctions about 
the degree of conclusiveness that can be achieved from adding 
a new RCT. Assuming that the control group event rate in the 
new RCT will be 5%, and that the RCT will yield a 25% relative 
risk reduction in TB, we approximated the required sample size 
for a future RCT in order to make the meta-analysis moderately 
and strongly conclusive. In technical terms, we approximated 
the sample size of a future RCT required for the cumulative 
meta-analysis Z-statistic to cross the TSA monitoring boundar-
ies demonstrating moderate evidence and the TSA monitoring 
boundaries demonstrating strong evidence.
Results
In our initial review, we identified 25 articles that poten-
tially fit our study criteria. Upon in-depth review, we 
excluded 16 trials from our analysis. Four RCTs did not 
meet our eligibility criteria since they did not include a 
placebo group.37–40 We excluded an additional study on the 
basis that it examined outcomes of isoniazid prophylaxis 
on HIV-positive children.47 We excluded an RCT of IHZ 
with placebo control because it did not disaggregate out-
comes of TB incidence by treatment group,48 and another 
because it evaluated only PPD+ patients.49 We excluded a 
study because it focused on the impact of IHZ on recurrent 
incidence of TB.33 Two manuscripts were long-term follow-
up studies of RCTs already identified by our review.50,51 
We excluded three conference abstracts on the basis that 
study findings have since been published in full text.34,52,53 
Finally, we excluded two additional conference posters 
and one manuscript since they were cohort studies.54–56 We 
included nine trials in our meta-analysis, comprising a total 
of 2,911 trial participants (Φ = 0.9, see Table 1). A total of 
1,526 study participants received INH and 1,385 placebo. 
Figure 1 presents the meta-analysis forest plot. The meta-
analysis relative risk is 0.74 (95% CI, 0.53–1.04, P = 0.082, 
I2 = 0%, P = 0.69).
Trial sequential analysis
We estimated that a meta-analysis information size of 
10,508 patients was required to yield moderate evidence, and 
that a meta-analysis information size of 19,920 patients was 
required to yield strong evidence. From our current analysis, 
the cumulative Z-statistic did not cross the TSA monitoring 
boundaries for moderate or strong evidence (Figure 2). 
This suggests that the pooled meta-analytic evidence of 
effectiveness is neither reliable nor definitive.
Topping up a sample size evaluation
We calculated that an additional 3,800 patients would need 
to be randomized (1,900 randomized to IHZ, and 1,900 
randomized to placebo) for the meta-analysis to yield 
moderate evidence of a 25% relative risk reduction. In 
technical terms, we calculated that a new trial showing a 
5% control group incidence rate and a 25% relative risk 
reduction would have to include 3,800 patients for the 
meta-analysis to cross the monitoring boundaries for mod-
erate evidence (ie, the monitoring boundaries based on the 
information size for moderate evidence, 10,508 patients). 
Figure 3 displays the scenario where such a trial has 
been added to the meta-analysis. Adding this trial to the 
meta-analysis would yield a meta-analysis information 
size of 6,711. The meta-analysis could thus be considered 
moderately conclusive 3,979 patients before reaching its 
required information size of 10,508.
We calculated that an additional 9000 patients would 
need to be randomized for the meta-analysis to yield strong 
evidence of a 25% relative risk reduction. In technical terms, 
we calculated that a new trial showing a 5% control group 
incidence rate and a 25% relative risk reduction would have 
to include 9000 patients for the meta-analysis to cross the Clinical Epidemiology 2010:2 61
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Figure 1 Forest plot of the individual trial RR estimates and 95% CIs, and the DerSimonian-Laird pooled RR estimate.
Notes: RR estimates smaller than 1.00 favor use of isoniazid chemoprophylaxis (IHZ) for prevention of tuberculosis in purified protein derivative negative HIV-infected 
  individuals, RR estimates larger than 1.00 favor controls.
Table 1 Study characteristic and outcomes for patients testing purified protein derivative – negative (PPD-)
Author,  
year
Trial  
location
Mean  
age  
(years)
Trial  
duration  
(months)
Trial  
follow-up  
(years)
Drug  
regimen  
(active)
Drug  
regimen  
(control)
No.  
patients  
(active)
No.  
patients  
(control)
TB  
incidence 
(active)
TB  
incidence 
(control)
Mohammed,  
2007
South  
Africa
39 12 NA INH 900  
or 800 mg  
twice weekly
Placebo 48 50 9 6
Rivero,  
2003
Spain 32 6 2 INH  
5 mg/kg  
to a max of  
300 mg daily
Placebo 83 77 3 4
Fitzgerald,  
2001
Haiti 32 12 2.5 INH  
300 mg 
daily + Vit B6 
50 mg
Placebo +  
Vit B6  
50 mg
126 111 6 4
Mwinga,  
1998
Zambia 30 6 1.6 INH  
300 mg  
twice weekly
Placebo 179 166 7 8
Gordin,  
1997
USA 38 6 2.8 INH  
300 mg + Vit B6 
50 mg
Placebo 260 257 3 6
Hawken,  
1997
Kenya 31 6 1.8 INH  
300 mg
Placebo 67 69 7 10
Whalen,  
1997
Uganda 30 6 1.3 (A)  
1.0 (C)
INH  
300 mg
Placebo 393 323 9 10
Pape,  
1993
Haiti 31 12 2.5 INH 300 mg  
+Vit B6 50 mg
+ Vit B6  
50 mg
20 35 2 5
Wadhawan,  
1993
Kenya NA 6 1.7 INH  
300 mg
Placebo 350 297 11 21
Abbreviations: NA, not applicable; INH, isoniazid; TB, tubercolosis.
monitoring boundaries for strong evidence (ie, the monitoring 
boundaries based on the information size for strong evidence, 
19,920 patients). Figure 4 displays the scenario where such 
a trial has been added to the meta-analysis. Adding this trial 
to the meta-analysis would yield a meta-analysis information 
size of 11,911. The meta-analysis could thus be considered 
moderately conclusive 8,009 patients before reaching its 
required information size of 19,920.Clinical Epidemiology 2010:2 62
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Discussion
Our study examined a public health and clinically impor-
tant topic that was able to include data from 9 RCTs. 
Despite a relative consistency of treatment effect across the 
trials, our meta-analysis is both inconclusive and lacking 
information to adequately guide clinical decision-mak-
ing. Based on our application of the TSA, we find that 
further trials including approximately 3,800 participants 
at a similar risk would be required to provide moderate 
evidence, and much more to provide strong evidence. To 
the extent that our example analysis applies to other meta-
analyses, including Cochrane reviews, many apparently 
conclusive meta-analyses may in fact provide indefinite 
answers.8,12,13
Trial sequential analysis represents one of several 
new developments in interpreting the utility of existing 
meta-analyses and other forms of evidence for clinical 
and policy decision-making. The GRADE Working 
Group, a guideline development panel that has created the 
GRADE profiler tool for inferring the quality of evidence, 
has recently included precision as one of five general 
components which determine the quality of evidence.3 
As a recent GRADE publication points out, inferring the 
precision of an intervention is based on more than the CIs of 
a study result and we should infer the plausibility of differing 
treatment effects according to precision and consistency of 
treatment effects.3
In addition to trial sequential analysis of the current 
meta-analysis data, our analysis provides an inference on 
the number of patients that would be required to be further 
randomized to provide stronger evidence. We refer to this as 
‘topping-up’ a sample size calculation, whereby if we plan a 
new clinical trial, we approximate the new number of patients 
required, with a similar risk profile, that must be randomized 
to create moderate quality meta-analytic evidence. In this 
example, it is 3,800 patients.
As with any analysis, there are strengths and limitations 
to consider. Our analysis is based on available data on an 
important public-health topic. We based our analysis on 
data from real RCTs and aimed to reduce publication bias 
and extraction of data bias by extensive searching and 
double data extraction. It is possible that other trials exist 
that we are unaware of. Furthermore, we distinctly chose 
this example of IHZ for TB prevention in HIV+ patients 
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Figure 2 Trial sequential analysis (TSA) monitoring boundaries for moderate and strong evidence (the downward sloping lines) in the current meta-analysis.
Notes: The monitoring boundaries were constructed using the Lan-DeMets alpha-spending approach corresponding to the O’Brien-Fleming boundaries. The monitoring 
boundaries for moderate evidence (alpha = 5%, beta = 20%) were based on information size required for moderate evidence (10,508 patients). The monitoring boundaries 
for strong evidence (alpha = 1%, beta = 10%) were based on information size required for strong evidence (19,920 patients). Both information size calculations were based on 
the assumption of a 5% incidence rate in the control group, and a 25% relative risk reduction. The cumulative Z-statistic does not cross above either of the two monitoring 
  boundaries, and thus, there is neither moderate or strong statistical evidence (significance) to support a treatment effect of at least a 25% relative risk reduction.Clinical Epidemiology 2010:2 63
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because we were aware that event rates were small and that 
this important public-health topic remains unanswered. It 
is possible that if we had chosen many other topics, we 
would not be able to demonstrate insufficiency, and hence 
this study is used as an example.
Furthermore, as with conventional sample size 
calculations for RCTs, our analyses are only reliable to the 
extent that the projected control group incidence rate and 
intervention effect is a good approximation of the “truth”. 
Our projected control group incidence rate and interven-
tion effect, reflect what we might realistically expect, given 
the current data. However, some future RCTs may include 
design features (high or low methodological quality, high or 
low risk population groups, variants of the intervention, etc.) 
which will render a higher or lower control group incidence 
rate and intervention effect. Deviations from the projected 
event rates may also occur due to the play of chance. As a 
result, a future RCT including the projected 3,800 patients 
will, in some situations, not be enough to make the meta-
analysis conclusive (ie, cross the monitoring boundaries for 
moderate evidence). We are, however, not too concerned 
with this issue. Firstly, in clinical research we never know 
the “truth”, and the uncertainty associated with any sample 
size estimation is simply an inherent and unavoidable part 
of the cumulative nature of science. Secondly, even in 
the situation where some future RCT does not make the 
meta-analysis conclusive according to the thresholds set 
by the monitoring boundaries, it will still provide valuable 
information to the existing body of evidence, and thus, 
allow for better informed policy making and planning of 
future research.
The role of meta-analysis in informing clinical and 
policy decision-making has received a tremendous amount 
of attention. Much less so, has been the adequate statistical 
interpretation of these analyses. Meta-analysis, particularly 
when including a small number of trials may overestimate 
the actual treatment effects of an intervention or yield false 
positive results.8,9 We have known for a considerable time 
that small trials may yield exaggerated treatment effects 
and spuriously small P-values compared to larger trials or 
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Figure 3 Trial sequential analysis (TSA) monitoring boundaries for moderate evidence (the downward sloping line) after adding a ‘fake trial’ with 3800 patients.
Notes: The monitoring boundaries for moderate evidence (alpha = 5%, beta = 20%) were constructed using the Lan-DeMets alpha-spending approach corresponding to 
the O’Brien-Fleming boundaries, and were based on the information size required for moderate evidence (10,508 patients). The information size calculation was based on 
the assumption of a 5% incidence rate in the control group, and a 25% relative risk reduction. The cumulative Z-statistic crossed the monitoring boundaries for moderate 
evidence after adding a ‘fake trial’ with an intervention effect estimate of a 25% relative risk reduction, a 5% control group incidence rate and 3800 patients (1900 in 
each group). This result demonstrates that under the event rate assumptions made for the information size calculations, a new trial would need to include 3800 patients 
(1900 in each group) to make the meta-analysis conclusive with moderate statistical support.Clinical Epidemiology 2010:2 64
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multiple trials pooled in a meta-analysis. Given the status that 
meta-analysis may receive in decision-making, falsely large 
treatment effects and spuriously small P-values may inhibit 
subsequent trials on the specific questions. This viewpoint 
suggests skepticism in interpreting small meta-analyses. 
Examples of meta-analyses generating falsely conclusive 
findings that are then refuted by subsequent larger trials are 
common.4,8,9,24
This is now an important time to refine our tools 
for inferring the quality and necessary conduct of these 
analyses. Recent reporting guidelines for meta-analysis, 
such as the PRISMA guidelines, make no reference to the 
adequacy of power and precision; and organizations such as 
The Cochrane Collaboration have had no written guidance 
on this issue.57 Given the small number of included trials 
within many Cochrane reviews this represents an important 
rallying opportunity for the conduct of future RCTs. Given 
the past emphasis on sample size calculations of individual 
trials that many organizations place on investigators, the 
number of patients and events should be given much greater 
consideration in meta-analysis.
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